Later, we combined CYP1A1, CYP2B6, CYP3A4, UGT1A8, UGT2B11, UGT2B17, UGT2B7, GAS5, XIST, SNHG6, which showed good correlations to chemotherapy or endocrine therapy resistance, to predict drug response and treatment outcomes in 69 PCa patients who have previously received chemotherapy or endocrine therapy. The gene discussed is UGT1A8; the disease is posterior cortical atrophy.